| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | XMD13-2 | GDSC1000 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | TAK-715 | GDSC1000 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | BRD-K20514654 | CTRPv2 | pan-cancer | AAC | 0.0092 | 0.9 |
| mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.0084 | 0.9 |
| mRNA | PF-3758309 | CTRPv2 | pan-cancer | AAC | 0.0082 | 0.9 |
| mRNA | SU11274 | CTRPv2 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | BRD-K86535717 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.9 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |